Cited by 2,302PARP inhibition in cancer therapyPancreatic and Hepatic Oncology ResearchBRCA gene mutations in cancer

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Open access

Golan, Talia, Hammel, Pascal, Reni, Michele, Van Cutsem, Eric, Macarulla, Teresa, Hall, Michael J., Park, Joon-Oh, Hochhauser, Daniel, Arnold, Dirk, Oh, Do-Youn, Reinacher-Schick, Anke, Tortora, Giampaolo, Algül, Hana, O’Reilly, Eileen M., McGuinness, David, Cui, Karen Y., Schlienger, Katia, Locker, Gershon Y., Kindler, Hedy L.·2019·New England Journal of Medicine

DOI 10.1056/nejmoa1903387PMC PMC6810605

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P = 0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs. 18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event. CONCLUSIONS: mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1903387

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citation
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citation
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269

Flagged first, then by citations

Show all 24 references

Sorted by citations

Items 801–900 of 1,002

Expression Patterns and Prognostic Value of DNA Damage Repair Proteins in Resected Pancreatic Neuroendocrine Neoplasms
Hua, J., Shi, S., Xu, J., Wei, M., Zhang, Y., Liu, J., Zhang, B., & Yu, X. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003884 · Cited by 15
DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition
Viera, T., & Patidar, P. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-76850-4 · Cited by 15
Pancreatic ductal adenocarcinoma in the era of precision medicine
Zheng-Lin, B., & O'Reilly, E. M. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.01.005 · Cited by 16
Self-citation
Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic
Gil, Y. R., Sánchez, P. J., Velasco, R. M., García, A. G., & Lobo, V. J. S.-A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042077 · Cited by 18
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma
Cleary, J. M., Wolpin, B. M., Dougan, S. K., Raghavan, S., Singh, H., Huffman, B. M., Sethi, N. S., Nowak, J. A., Shapiro, G. I., Aguirre, A. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1367 · Cited by 16
Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
Seo, H.-R., Nam, A., Bang, J., Oh, K.-S., Kim, J., Yoon, J., Kim, T., & Oh, D. (2021) · Cancer Research and Treatment · doi:10.4143/crt.2021.473 · Cited by 15
Self-citation
Determinants of Homologous Recombination Deficiency in Pancreatic Cancer
Wattenberg, M. M., & Reiss, K. A. (2021) · Cancers · doi:10.3390/cancers13184716 · Cited by 15
Functional Characteristics and Regulated Expression of Alternatively Spliced Tissue Factor: An Update
Matiash, K., Lewis, C. S., & Bogdanov, V. Y. (2021) · Cancers · doi:10.3390/cancers13184652 · Cited by 15
Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives (Review)
Pekarek, L., Fraile‐Μartinez, O., Montero, C. G., Álvarez-Mon, M. Á., Acero, J., Ruiz‑Llorente, L., García‐Honduvilla, N., Albillos, A., Buján, J., Álvarez‐Mon, M., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.13070 · Cited by 15
SETD8 induces stemness and epithelial–mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression
Liu, M., Shi, Y., Hu, Q., Qin, Y., Ji, S., Liu, W., Zhuo, Q., Fan, G., Zeng, Y., Song, C., et al. (2021) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmab140 · Cited by 15
Multi-omics landscape and clinical significance of a SMAD4 -driven immune signature: Implications for risk stratification and frontline therapies in pancreatic cancer
Wang, L., Liu, Z., Zhu, R., Liang, R., Wang, W., Li, J., Zhang, Y., Guo, C., Han, X., & Sun, Y. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.02.031 · Cited by 15
Identification and Management of Pathogenic Variants in BRCA1 , BRCA2 , and PALB2 in a Tumor-Only Genomic Testing Program
Bychkovsky, B., Li, T., Sotelo, J., Tayob, N., Mercado, J. M., Gomy, I., Chittenden, A. B., Kane, S. R., Stokes, S., Hughes, M. E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2861 · Cited by 15
Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
Zhou, T., Mahn, R., Möhring, C., Sadeghlar, F., Meyer, C. H., Toma, M. I., Kreppel, B., Essler, M., Glowka, T. R., Matthaei, H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.933943 · Cited by 18
Sequential evaluation of MUC promoter methylation using next‐generation sequencing‐based custom‐made panels in liquid‐based cytology specimens of pancreatic cancer
Yokoyama, S., Iwaya, H., Akahane, T., Hamada, T., Higashi, M., Hashimoto, S., Tanoue, S., Ohtsuka, T., Ido, A., & Tanimoto, A. (2022) · Diagnostic Cytopathology · doi:10.1002/dc.25022 · Cited by 15
Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples
Redegalli, M., Grassini, G., Magliacane, G., Pecciarini, L., Lena, M. S., Smart, C. E., Johnston, R. L., Waddell, N., Maestro, R., Macchini, M., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.10.014 · Cited by 15
Self-citation
Treatment of pancreatic cancer in 2022
Casolino, R., & Biankin, A. V. (2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2 · Cited by 15
A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer
de Geus, S. W. L., & Sachs, T. E. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13281-1 · Cited by 15
Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis
Franck, C., Canbay, A. E., Malfertheiner, P., & Venerito, M. (2019) · Journal of Oncology · doi:10.1155/2019/5832309 · Cited by 15
The prognostic and predictive value of the albumin-bilirubin score in advanced pancreatic cancer
Zhang, T., Yin, R., & Wang, L. (2020) · Medicine · doi:10.1097/md.0000000000020654 · Cited by 15
Maintenance Olaparib for Metastatic Pancreatic Cancer
Puccini, A., Bregni, G., & Sciallero, S. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1911185 · Cited by 15
Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistancePreprint
Pandya, D. S., Shah, M., Kaplan, F., Martino, C., Levy, G. H., Kazanjian, M., Batter, S., Martignetti, J. A., & Frank, R. C. (2021) · Molecular Case Studies · doi:10.1101/mcs.a005801 · Cited by 17
Proteomics in pancreatic cancer
Cai, F., Gu, Y., Ling, Y., Yi, G., Zang, S., Su, T., Liu, Y., Li, A., Wang, D., Zhao, W., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00805-y · Cited by 19
Detecting likely germline variants during tumor-based molecular profiling
Jaber, D. A., Zhang, J., & Godley, L. A. (2025) · Journal of Clinical Investigation · doi:10.1172/jci190264 · Cited by 13
Genetic cancer predisposition syndromes among older adults
Chávarri-Guerra, Y., Slavin, T. P., Longoria, O., & Weitzel, J. N. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.01.001 · Cited by 16
Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling
Ettrich, T. J., Sturm, N., Güthle, M., Hüttner, F. J., & Perkhofer, L. (2022) · Visceral Medicine · doi:10.1159/000521631 · Cited by 14
Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board
Green, M. F., Watson, C., Tait, S. D., He, J., Pavlick, D. C., Frampton, G. M., Riedel, J., Plichta, J. K., Armstrong, A. J., Previs, R. A., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac164 · Cited by 14
Comprehensive Analysis of Adverse Events Induced by PARP Inhibitors Using JADER and Time to Onset
Yamaoka, K., Fujiwara, M., Uchida, M., Uesawa, Y., Muroi, N., & Shimizu, T. (2022) · Life · doi:10.3390/life12091355 · Cited by 14
Role of genetic testing in hepatic, pancreatic, and biliary cancers
Hewitt, D. B., Aziz, H., Brown, Z. J., & Pawlik, T. M. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101844 · Cited by 14
Health-Related Quality of Life of Patients with Metastatic Pancreatic Cancer: A Systematic Literature Review
Yoo, H. K., Patel, N. R., Joo, S., Amin, S., Hughes, R., & Chawla, R. (2022) · Cancer Management and Research · doi:10.2147/cmar.s376261 · Cited by 14
Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma
Topham, J. T., Renouf, D. J., & Schaeffer, D. F. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231157651 · Cited by 14
Precision Medicine and Immunotherapy Have Arrived for Cholangiocarcinoma: An Overview of Recent Approvals and Ongoing Clinical Trials
Karasic, T. B., Eads, J. R., & Goyal, L. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00573 · Cited by 13
Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors
Yu, X., Zhu, L., Wang, T., Li, L., Liu, J., Che, G., & Zhou, Q. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188910 · Cited by 14
MEK Inhibition Sensitizes Pancreatic Cancer to STING Agonism by Tumor Cell–intrinsic Amplification of Type I IFN Signaling
Ghukasyan, R., Liang, K., Chau, K., Li, L., Chan, C., Abt, E. R., Le, T. M., Park, J. Y., Wu, N., Premji, A., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3322 · Cited by 14
Self-citation
Blockage of retinoic acid signaling via RARγ suppressed the proliferation of pancreatic cancer cells by arresting the cell cycle progression of the G1-S phase
Yamakawa, K., Koyanagi‐Aoi, M., Machinaga, A., Kakiuchi, N., Hirano, T., Kodama, Y., & Aoi, T. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02928-4 · Cited by 14
Biological and clinical implications of early-onset cancers: A unique subtype
He, T., Li, J., Xu, Z., Chen, Q., Yin, H., Pu, N., Wang, W., & Liu, L. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104120 · Cited by 15
Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer
Quiñonero, F., Torrejón, B. P., Ramírez‐Rodríguez, G. B., Garcés, V., Delgado‐López, J. M., Jiménez‐Luna, C., Perazzoli, G., Melguizo, C., Prados, J. C., & Ortíz, R. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s415631 · Cited by 14
KPT330 promotes the sensitivity of glioblastoma to olaparib by retaining SQSTM1 in the nucleus and disrupting lysosomal function
Wang, L., Wei, S., Yuan, Y., Zhong, M.-J., Wang, J., Yan, Z., Zhou, K., Luo, T., Li, L., & Bian, X. (2023) · Autophagy · doi:10.1080/15548627.2023.2252301 · Cited by 16
CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines
Witz, A., Dardare, J., François, A., Husson, M., Rouyer, M., Demange, J., Merlin, J., Gilson, P., & Harlé, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-45964-w · Cited by 17
Targeting Polymerase Theta (POLθ) for Cancer Therapy
Patterson-Fortin, J., & D’Andrea, A. D. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-30065-3_15 · Cited by 16
ASO Practice Guidelines Series: Management of Resectable, Borderline Resectable, and Locally Advanced Pancreas Cancer
Turner, K. M., Wilson, G. C., Patel, S. H., & Ahmad, S. A. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14585-y · Cited by 14
Combinatorial Approaches for Chemotherapies and Targeted Therapies With Radiation: United Efforts to Innovate in Patient Care
Jabbour, S. K., Kumar, R. N., Anderson, B. M., Chino, J., Jethwa, K. R., McDowell, L. J., Lo, A., Owen, D., Pollom, E. L., Tree, A. C., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.010 · Cited by 14
Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives
Toledo, B., Deiana, C., Scianò, F., Brandi, G., Marchal, J. A., Perán, M., & Giovannetti, E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2319340 · Cited by 15
Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid Tumors
Szentmártoni, G., Mühl, D., Csanda, R., Szász, A. M., Herold, Z., & Dank, M. (2024) · Biomedicines · doi:10.3390/biomedicines12030593 · Cited by 15
Blood-Based microRNA Biomarker Signature of Early-Stage Pancreatic Ductal Adenocarcinoma With Lead-Time Trajectory in Prediagnostic Samples
Treekitkarnmongkol, W., Dai, J., Liu, S., Sankaran, D., Nguyen, T., Balasenthil, S., Hurd, M. W., Chen, M., Katayama, H., Roy‐Chowdhuri, S., et al. (2024) · Gastro Hep Advances · doi:10.1016/j.gastha.2024.08.002 · Cited by 14
Targeting KRAS ‐mutant pancreatic cancer through simultaneous inhibition of KRAS , MEK, and JAK2
Miyazaki, S., Kitazawa, M., Nakamura, S., Koyama, M., Yamamoto, Y., Hondo, N., Kataoka, M., Tanaka, H., Takeoka, M., Komatsu, D. D., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13751 · Cited by 16
SMAD4 Limits PARP1 dependent DNA Repair to Render Pancreatic Cancer Cells Sensitive to Radiotherapy
Wang, Y., Yu, T., Zhao, Z., Li, X., Song, Y., He, Y., Zhou, Y., Li, P., An, L., & Wang, F. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07210-7 · Cited by 14
An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor
Borazanci, E. H., Korn, R. L., Liang, W. S., Guarnieri, C. M., Haag, S. G., Snyder, C. E., Hendrickson, K., Caldwell, L., Hoff, D. V., & Jameson, G. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0905 · Cited by 14
Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?
Nishikawa, G., Booth, C. M., & Prasad, V. K. (2020) · Cancer · doi:10.1002/cncr.32979 · Cited by 14
Comprehensive analysis of gene regulation network and immune signatures of prognostic biomarker YAP1 in pancreatic cancer
Yang, Y., Zheng, Y., Liu, X., Ji, R., Chen, Z., Guo, Q., Wu, G., Wang, Y., & Zhou, Y. (2020) · Journal of Cancer · doi:10.7150/jca.49117 · Cited by 14
Future directions in drug development in pancreatic cancer
Lambert, A., Conroy, T., & Ducreux, M. P. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.02.002 · Cited by 14
Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer
Hong, J. Y., Cho, H. J., Kim, S. T., Park, Y. S., Shin, S. H., Han, I. W., Lee, J., Heo, J. S., & Park, J. O. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211038478 · Cited by 14
Self-citation
Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
Bajrami, I., Walker, C., Krastev, D. B., Weekes, D. B., Song, F., Wicks, A. J., Alexander, J. J., Haider, S. A., Brough, R., Pettitt, S. J., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02770-2 · Cited by 16
BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients
Park, J. H., Jo, J. H., Jang, S. I., Chung, M. J., Park, J. Y., Bang, S., Park, S. W., Song, S. Y., Lee, H. S., & Cho, J. H. (2022) · Cancers · doi:10.3390/cancers14010236 · Cited by 14
Self-citation
Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report
Wang, Z., Du, H., Chen, C., Liu, X., & Ke, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.801320 · Cited by 14
Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC
Cattolico, C., Bailey, P., & Barry, S. T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.816517 · Cited by 17
Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights
Kole, C., Charalampakis, N., Tsakatikas, S., Frountzas, M., Apostolou, K. G., & Schizas, D. (2022) · Cancer Management and Research · doi:10.2147/cmar.s267260 · Cited by 18
The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways
Yin, C., Alqahtani, A. J., & Noel, M. S. (2022) · Cancers · doi:10.3390/cancers14112619 · Cited by 14
CT Radiomics and Whole Genome Sequencing in Patients with Pancreatic Ductal Adenocarcinoma: Predictive Radiogenomics Modeling
Hinzpeter, R., Kulanthaivelu, R., Kohan, A. A., Avery, L. M., Pham, N., Ortega, C., Metser, U., Haider, M. A., & Veit‐Haibach, P. (2022) · Cancers · doi:10.3390/cancers14246224 · Cited by 13
Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients with Pancreatic Cancer or Suspected Related Hereditary Syndromes: Historical Prospective Analysis
Buono, A. D., Poliani, L., Greco, L., Bianchi, P. P., Barile, M., Giatti, V., Bonifacio, C., Carrara, S., Malesci, A., & Laghi, L. (2023) · Cancers · doi:10.3390/cancers15061852 · Cited by 17
ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738
Jette, N., Radhamani, S., Ye, R., Yu, Y., Arthur, G., Goutam, S., Bismar, T. A., Kumar, M., Bose, P., Yip, S., et al. (2020) · Genome Instability & Disease · doi:10.1007/s42764-020-00011-0 · Cited by 14
Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities
Wang, Y., Lakoma, A., & Zogopoulos, G. (2020) · Genes · doi:10.3390/genes11091098 · Cited by 14
Current status and future prospect of surgical treatment for pancreatic cancer
Yang, Y. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.12.04 · Cited by 14
Mutational signatures reveal mutual exclusivity of homologous recombination and mismatch repair deficiencies in colorectal and stomach tumors
Farmanbar, A., KNELLER, R. W., & Firouzi, S. (2023) · Scientific Data · doi:10.1038/s41597-023-02331-8 · Cited by 14
Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing Platforms
Marconato, N., Tommasi, O. D., Paladin, D., Boscarino, D., Spagnol, G., Saccardi, C., Maggino, T., Tozzi, R., Noventa, M., & Marchetti, M. (2025) · Cancers · doi:10.3390/cancers17111771 · Cited by 15
Experimental models of pancreas cancer: what has been the impact for precision medicine?
Pantazopoulou, V., Kubota, C. S., Ogawa, S., Gulay, K. C. M., Lin, X., Song, H., Weitz, J., Tiriac, H., Lowy, A. M., & Engle, D. D. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191945 · Cited by 16
Pancreatic cancer
Roth, S., Apte, M. V., Balachandran, V. P., Biffi, G., Conroy, T., Cukierman, E., Dotan, E., Esposito, I., Grünwald, B. T., Klauß, M., et al. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00699-6 · Cited by 19
Self-citation
PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
Teyssonneau, D., Thiery-Vuillemin, A., Dariane, C., Barret, É., Beauval, J., Brureau, L., Créhange, G., Fiard, G., Fromont, G., Gauthé, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061734 · Cited by 15
Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes
Tsumura, T., Doi, K., & Marusawa, H. (2022) · Cancers · doi:10.3390/cancers14153674 · Cited by 15
Efficacy of dabrafenib/trametinib in pancreatic ductal adenocarcinoma with BRAF NVTAP deletion: A case report
Shin, J. E., An, H. J., Park, H. S., Kim, H., & Shim, B. Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.976450 · Cited by 14
Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications
Nguyen, T. T., Hamdan, D., Angeli, E., Feugeas, J., Le, Q. V., Pamoukdjian, F., & Bousquet, G. (2023) · Cancers · doi:10.3390/cancers15061728 · Cited by 15
Personalized treatment in localized pancreatic cancer
Neoptolemos, J. P., Hu, K., Bailey, P. J., Springfeld, C., Cai, B., Miao, Y., Michalski, C. W., Carvalho, C. T., Hackert, T., & Büchler, M. W. (2023) · European surgery. Supplement/European surgery · doi:10.1007/s10353-023-00814-x · Cited by 13
Successful Combination of Olaparib and 225Ac-Dotatate in a Patient with Neuroendocrine Tumor G3 and BRCA Mutation
Kröcher, A., Folprecht, G., Winzer, R., Sergon, M., Bornhäuser, M., Kotzerke, J., & Brogsitter, C. (2023) · Case Reports in Oncology · doi:10.1159/000533198 · Cited by 13
Synergistic antitumor efficacy of rMV-Hu191 and Olaparib in pancreatic cancer by generating oxidative DNA damage and ROS-dependent apoptosis
Zhang, C., Li-hong, J., Zhou, X., He, Y.-P., Liu, Y., Zhou, D., Lv, Y., Wu, B., & Zhao, Z. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101812 · Cited by 14
Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges
Szczepanski, J. M., Rudolf, M. A., & Shi, J. (2024) · Cancers · doi:10.3390/cancers16040794 · Cited by 15
Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials
Lesan, V., Olivier, T., & Prasad, V. K. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114022 · Cited by 15
Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma
Klatte, D. C. F., Starr, J. S., Clift, K. E., Hardway, H., van Hooft, J. E., van Leerdam, M. E., Potjer, T. P., Presutti, R. J., Riegert‐Johnson, D. L., Wallace, M. B., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00447 · Cited by 13
ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients
Huerta, M., Martín-Arana, J., Gimeno-Valiente, F., Carbonell‐Asins, J. A., García-Micó, B., Martínez-Castedo, B., Robledo-Yagüe, F., Camblor, D. G., Fleitas, T., Bartolomé, M. G., et al. (2024) · Translational research · doi:10.1016/j.trsl.2024.05.003 · Cited by 16
Recent Advances in Genomic Approaches for the Detection of Homologous Recombination Deficiency
Kim, Y., Gulhan, D., Jin, H., Głodzik, D., & Park, P. J. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.154 · Cited by 13
Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends
Thapa, B., Sarkar, N. D., Giri, S., Sharma, K., Kim, M., & Kilari, D. (2024) · Cancer Management and Research · doi:10.2147/cmar.s411023 · Cited by 13
Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence
Moosavi, F., Hassani, B., Nazari, S., Saso, L., & Firuzi, O. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189185 · Cited by 14
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)
Witte, D. P., Pretzell, I., Reißig, T. M., Stein, A., Velthaus, J.-L., Alig, A. H. S., Bohnenberger, H., Knödler, M., Kurreck, A., Sulzer, S., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05954-5 · Cited by 15
Self-citation
Investigating synthetic lethality and PARP inhibitor resistance in pancreatic cancer through enantiomer differential activity
Masi, M., Poppi, L., Previtali, V., Nelson, S. R., Wynne, K. J., Varignani, G., Falchi, F., Veronesi, M., Albanesi, E., Tedesco, D., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02382-3 · Cited by 19
A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancer
Calheiros, J., Silva, R., Barbosa, F., Morais, J., Moura, S. R., Almeida, S., Fiorini, E., Mulhovo, S., Aguiar, T. Q., Wang, T., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03389-5 · Cited by 13
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Wang, L., Wang, Q., Xu, Y., Cui, M., & Han, L. (2019) · Current Drug Targets · doi:10.2174/1389450120666190925123507 · Cited by 14
The DNA damaging revolution
Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103117 · Cited by 13
Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017
Ding, D., Javed, A. A., Cunningham, D., Teinor, J. A., Wright, M. J., Javed, Z. N., Wilt, C., Parish, L., Hodgin, M. B., Ryan, A., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.039 · Cited by 14
Routine Molecular Pathology Diagnostics in Precision Oncology
Wenzel, C., Herold, S., Wermke, M., Aust, D. E., & Baretton, G. B. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0025 · Cited by 14
miR-373 Suppresses Cell Proliferation and Apoptosis via Regulation of SIRT1/PGC-1α/NRF2 Axis in Pancreatic Cancer.
Yin, Q., Zhou, Y., & Li, Z. H. Y. (2021) · PubMed Central · doi:10.22074/cellj.2021.7038 · Cited by 13
The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol
Ursprung, S., Mossop, H., Gallagher, F. A., Sala, E., Skells, R., Sipple, J., Mitchell, T. J., Chhabra, A., Fife, K. M., Matakidou, A., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08965-4 · Cited by 14
Study protocol for a multi-institutional prospective surveillance study among kindreds with familial pancreatic cancer and individuals with hereditary pancreatic cancer syndrome: The Diamond Study
Hijioka, S., Morizane, C., Takaori, K., & Okusaka, T. (2022) · Pancreatology · doi:10.1016/j.pan.2022.04.006 · Cited by 13
Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy
Murai, K., Kodama, T., Hikita, H., Shimoda, A., Fukuoka, M., Fukutomi, K., Shigeno, S., Shiode, Y., Motooka, D., Higuchi, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2014 · Cited by 14
Antibody-Based Approaches to Target Pancreatic Tumours
Sorbara, M., Cordelier, P., & Béry, N. (2022) · Antibodies · doi:10.3390/antib11030047 · Cited by 15
Novel and emerging therapies in pulmonary arterial hypertension
Cassady, S. J., Soldin, D., & Ramani, G. V. (2022) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2022.1022971 · Cited by 14
The Current Status of DNA-Repair-Directed Precision Oncology Strategies in Epithelial Ovarian Cancers
Tang, H., Kulkarni, S., Peters, C., Eddison, J., Al-Ani, M., & Madhusudan, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087293 · Cited by 13
Network pharmacology of apigeniflavan: a novel bioactive compound of Trema orientalis Linn. in the treatment of pancreatic cancer through bioinformatics approaches
Das, R., Agrawal, S., Kumar, P., Singh, A. K., Shukla, P. K., Bhattacharya, I., Tiwari, K. N., Mishra, S. K., & Tripathi, A. K. (2023) · 3 Biotech · doi:10.1007/s13205-023-03570-7 · Cited by 13
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
Reshkin, S. J., Cardone, R. A., & Koltai, T. (2024) · Cells · doi:10.3390/cells13070602 · Cited by 14
Usefulness of rapid on-site evaluation specimens from endoscopic ultrasound-guided fine-needle aspiration for cancer gene panel testing: A retrospective study
Ishizawa, T., Makino, N., Matsuda, A., Kakizaki, Y., Kobayashi, T., Ikeda, C., Sugahara, S., Tsunoda, M., & Ueno, Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228565 · Cited by 13
Mucinous Histology, BRCA1/2 Mutations, and Elevated Tumor Mutational Burden in Colorectal Cancer
Harpaz, N., Gatt, Y. E., Granit, R. Z., Fruchtman-Brot, H., Hubert, A., & Grinshpun, A. (2020) · Journal of Oncology · doi:10.1155/2020/6421205 · Cited by 13
Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)
Okano, N., Morizane, C., Nomura, S., Takahashi, H., Tsumura, H., Satake, H., Mizuno, N., Tsuji, K., Shioji, K., Asagi, A., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01721-x · Cited by 13
ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms
Hamada, T., Oyama, H., Nakai, Y., Tada, M., Koh, H., Tateishi, K., Arita, J., Hakuta, R., Ijichi, H., Ishigaki, K., et al. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-1581 · Cited by 13

Authors: Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O’Reilly, E. M., McGuinness, D., Cui, K. Y., Schlienger, K., Locker, G. Y., & Kindler, H. L.
Affiliations: Tel Aviv University (IL)
From the Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (T.G.); Hôpital Beaujon (Assistance Publique–Hôpitaux de Paris), Clichy, and University Paris VII, Paris (P.H.); IRCCS Ospedale San Raffaele Scientific Institute, Milan (M.R.), Azienda Ospedaliera Universitaria Integrata Verona, Verona (G.T.), and Fondazione Policlinico Universitario Gemelli IRCCS, Rome (G.T.) — all in Italy; University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium (E.V.C.); Vall...
ORCID: Golan, Talia
Hammel, Pascal
Reni, Michele
Macarulla, Teresa
Hall, Michael J.
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Tortora, Giampaolo
Algül, Hana
McGuinness, David
Cui, Karen Y.
Locker, Gershon Y.
Kindler, Hedy L.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2019-07-25
Volume: 381
Issue: 4
Pages: 317-327
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1903387
PMC: PMC6810605
OpenAlex: W2947826965
Cited by: 2,302
References: 24
Citations by year: 2026: 195 · 2025: 268 · 2024: 292 · 2023: 312 · 2022: 412 · 2021: 452 · 2020: 299 · 2019: 66
FWCI: 129.05
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
UCL Discovery (University College London) (submittedVersion)
Lirias (submittedVersion)
mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by-nc-nd)
Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders: AstraZeneca (NA)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc (NA)
NIH/NCI Cancer Center Support Grant (P30-17 CA008748)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: olaparib, PARP inhibitors, germline BRCA mutation, metastatic pancreatic cancer, maintenance therapy, progression-free survival, overall survival, quality of life, adverse events, platinum-based chemotherapy, PARP inhibitor resistance, DNA repair deficiency, targeted therapy, interim analysis, predictive biomarkers, treatment discontinuation, health-related quality of life
MeSH terms: Progression-Free Survival, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pancreatic Neoplasms, Phthalazines, Piperazines, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Kaplan-Meier Estimate, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks